Louis Thomeret
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Louis Thomeret has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Annabel Berthon
Section on Endocrinology & Genetics (SEGEN), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA
3 shared publications Anne Jouinot
Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France
3 shared publications- Fidéline Bonnet-Serrano
Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France
3 shared publications - Florian Violon
Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France
3 shared publications - Jérôme Bertherat
Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France
3 shared publications - Lucas Bouys
Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France
3 shared publications
Latest Publications
- 5 October 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (4) , 667-676
Diagnostic utility of diurnal salivary cortisol profiles in neoplastic and nonneoplastic hypercortisolism
Objective: Salivary cortisol has the advantages of being noninvasive, readily accessible in ambulatory patients and reflecting the free bioactive fraction of cortisol. The cortisol diurnal cycle, based on 6 samples collected every 4 h over a 24-h period, allows a detailed characterization of cortisol variations throughout the day. The objective of this study was to assess the value of the salivary cortisol diurnal cycle for the diagnosis of Cushing's syndrome (CS) and the differential diagnosis of nonneoplastic hypercortisolism. Design: This retrospective cohort study included all the patients hospitalized in Endocrinology department of Cochin Hospital between 2012 and 2018 who had complete serum and salivary diurnal cycle assessments. Methods: Serum and salivary cortisol levels were measured using an automated and a radio immunoassay, respectively. Results: A total of 227 subjects without CS, 46 patients with nonneoplastic CS, 72 patients with ACTH-dependent CS, and 67 with adrenal CS were included. For the diagnosis of CS, the cortisol nadir throughout the day showed better diagnostic performance than midnight cortisol, both in serum and saliva with, area under the receiver operating characteristic curves (ROC AUCs) of 0.98 and of 0.96, respectively. For the differential diagnosis between nonneoplastic hypercortisolism and ACTH-dependent CS, salivary cortisol showed better diagnostic performance than midnight serum cortisol (ROC AUC 0.97; optimal cutoff 5.3 nM; sensitivity 90%; and specificity 87% for the salivary cortisol nadir). Conclusion: The salivary cortisol diurnal cycle appears to be a powerful tool for the diagnosis of CS and for the challenging differential diagnosis of nonneoplastic hypercortisolism, with the major advantage of being accessible in ambulatory patients.
- 5 October 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (4) , 667-676
Diagnostic utility of diurnal salivary cortisol profiles in neoplastic and nonneoplastic hypercortisolism
Objective: Salivary cortisol has the advantages of being noninvasive, readily accessible in ambulatory patients and reflecting the free bioactive fraction of cortisol. The cortisol diurnal cycle, based on 6 samples collected every 4 h over a 24-h period, allows a detailed characterization of cortisol variations throughout the day. The objective of this study was to assess the value of the salivary cortisol diurnal cycle for the diagnosis of Cushing's syndrome (CS) and the differential diagnosis of nonneoplastic hypercortisolism. Design: This retrospective cohort study included all the patients hospitalized in Endocrinology department of Cochin Hospital between 2012 and 2018 who had complete serum and salivary diurnal cycle assessments. Methods: Serum and salivary cortisol levels were measured using an automated and a radio immunoassay, respectively. Results: A total of 227 subjects without CS, 46 patients with nonneoplastic CS, 72 patients with ACTH-dependent CS, and 67 with adrenal CS were included. For the diagnosis of CS, the cortisol nadir throughout the day showed better diagnostic performance than midnight cortisol, both in serum and saliva with, area under the receiver operating characteristic curves (ROC AUCs) of 0.98 and of 0.96, respectively. For the differential diagnosis between nonneoplastic hypercortisolism and ACTH-dependent CS, salivary cortisol showed better diagnostic performance than midnight serum cortisol (ROC AUC 0.97; optimal cutoff 5.3 nM; sensitivity 90%; and specificity 87% for the salivary cortisol nadir). Conclusion: The salivary cortisol diurnal cycle appears to be a powerful tool for the diagnosis of CS and for the challenging differential diagnosis of nonneoplastic hypercortisolism, with the major advantage of being accessible in ambulatory patients.
- 12 January 2026
- Published by Springer Nature in Endocrine Pathology
- Vol. 37 (1) , 3
The Proteome of Bilateral Macronodular Adrenocortical Disease (BMAD) Shows Different Profiles Correlating with the Genetic Causes and Reveals Specific Dysregulation of RNA Polymerase II and Cholesterol Biosynthesis Enzymes
- 12 January 2026
- Published by Springer Nature in Endocrine Pathology
- Vol. 37 (1) , 3
The Proteome of Bilateral Macronodular Adrenocortical Disease (BMAD) Shows Different Profiles Correlating with the Genetic Causes and Reveals Specific Dysregulation of RNA Polymerase II and Cholesterol Biosynthesis Enzymes
- 26 November 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (6) , 733-744
PRKACA constitutional duplication: a specific cause of primary pigmented nodular adrenocortical disease
Objective: Constitutional duplications of PRKACA (PRKACAdup) have been described in rare cases of bilateral nodular adrenocortical disease (BNAD). The aim here was to clarify the phenotype in case of PRKACAdup, through systematic screening in BNAD patients, and study the molecular mechanisms involved. Methods: Between 2020 and 2024, 781 index cases (IC) with BNAD (693 bilateral macronodular hyperplasia and 88 primary pigmented nodular adrenocortical diseases [PPNAD]) were genotyped using next-generation sequencing with a panel targeting ARMC5, KDM1A, MEN1, PRKAR1A, PRKACA, or whole-genome sequencing (WGS). Chromatin conformation analyses were performed with Hi-C libraries generated from 3 tumors. Results: PRKACAdup was identified in 8/781 IC and 8/12 screened relatives. WGS performed on 4 IC presenting with PPNAD revealed no other genetic alterations in genes associated with human pathology within the duplicated region, nor any other alterations related to adrenal pathology. All IC with PRKACAdup underwent adrenalectomy for ACTH-independent hypercortisolism, with pathology confirming PPNAD. Other manifestations of Carney complex were observed in 8 of the 16 patients with PRKACAdup, limited to lentiginosis and benign tumors of the gonads. Immunohistochemistry using PRKACA/PRKAR1A antibodies facilitated the differentiation of the responsible genetic alteration. PRKACAdup was found to generate topologically associated neo-domains, in tumor Hi-C maps, as compared to controls. Conclusions: PRKACAdup causes PPNAD but no other forms of BNAD, so these should be sought in the absence of pathogenic PRKAR1A variants.
- 26 November 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (6) , 733-744
PRKACA constitutional duplication: a specific cause of primary pigmented nodular adrenocortical disease
Objective: Constitutional duplications of PRKACA (PRKACAdup) have been described in rare cases of bilateral nodular adrenocortical disease (BNAD). The aim here was to clarify the phenotype in case of PRKACAdup, through systematic screening in BNAD patients, and study the molecular mechanisms involved. Methods: Between 2020 and 2024, 781 index cases (IC) with BNAD (693 bilateral macronodular hyperplasia and 88 primary pigmented nodular adrenocortical diseases [PPNAD]) were genotyped using next-generation sequencing with a panel targeting ARMC5, KDM1A, MEN1, PRKAR1A, PRKACA, or whole-genome sequencing (WGS). Chromatin conformation analyses were performed with Hi-C libraries generated from 3 tumors. Results: PRKACAdup was identified in 8/781 IC and 8/12 screened relatives. WGS performed on 4 IC presenting with PPNAD revealed no other genetic alterations in genes associated with human pathology within the duplicated region, nor any other alterations related to adrenal pathology. All IC with PRKACAdup underwent adrenalectomy for ACTH-independent hypercortisolism, with pathology confirming PPNAD. Other manifestations of Carney complex were observed in 8 of the 16 patients with PRKACAdup, limited to lentiginosis and benign tumors of the gonads. Immunohistochemistry using PRKACA/PRKAR1A antibodies facilitated the differentiation of the responsible genetic alteration. PRKACAdup was found to generate topologically associated neo-domains, in tumor Hi-C maps, as compared to controls. Conclusions: PRKACAdup causes PPNAD but no other forms of BNAD, so these should be sought in the absence of pathogenic PRKAR1A variants.
- 14 June 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (1) , 106-116
Unexpected discrepancies between steroid intra-tissular content in adrenal tumors and clinical diagnosis of steroid excess
Objective: Adrenocortical tumor (ACT) morbidity is associated with steroid secretion, depending on tumor type. Indeed, adrenal steroidogenesis is a finely regulated process, altered in ACT. These alterations are usually characterized by blood steroid assays, also depending on steroid gonadal production and metabolism. Our aim was to determine steroid content directly in ACT tissues and to compare it with clinical diagnosis of steroid excess. Methods: A profile of 13 steroids was analyzed in ultra-high-performance liquid chromatography coupled to tandem mass spectrometry (Thermo Fisher Scientific®) in frozen tissue samples from 75 ACT, 7 Cushing's disease, and 9 normal adrenals. Results: Steroid levels were 10-1000 times higher in tissue from normal adrenal than normal concentrations expected in blood. Concentration ratios between tissue from normal adrenal and blood reference values were lower for distal products than for steroid precursors. In adrenocortical cancers, intra-tissular steroid content was lower than in unilateral benign tumors despite clear clinical steroid excess. Unexpectedly, in overt-Cushing adenomas, intra-tissular cortisol levels were not higher and androstenedione levels were not lower than in non-functioning adenomas. Adrenal differentiation score based on transcriptome was well correlated with intra-tissular cortisol levels. Conclusion: Discrepancies observed between steroid levels measured in ACT tissue and clinical diagnosis of steroid excess suggest a dysregulation of steroid export depending on tumor type, opening new perspectives for diagnosis and treatment of steroid excess.
- 14 June 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (1) , 106-116
Unexpected discrepancies between steroid intra-tissular content in adrenal tumors and clinical diagnosis of steroid excess
Objective: Adrenocortical tumor (ACT) morbidity is associated with steroid secretion, depending on tumor type. Indeed, adrenal steroidogenesis is a finely regulated process, altered in ACT. These alterations are usually characterized by blood steroid assays, also depending on steroid gonadal production and metabolism. Our aim was to determine steroid content directly in ACT tissues and to compare it with clinical diagnosis of steroid excess. Methods: A profile of 13 steroids was analyzed in ultra-high-performance liquid chromatography coupled to tandem mass spectrometry (Thermo Fisher Scientific®) in frozen tissue samples from 75 ACT, 7 Cushing's disease, and 9 normal adrenals. Results: Steroid levels were 10-1000 times higher in tissue from normal adrenal than normal concentrations expected in blood. Concentration ratios between tissue from normal adrenal and blood reference values were lower for distal products than for steroid precursors. In adrenocortical cancers, intra-tissular steroid content was lower than in unilateral benign tumors despite clear clinical steroid excess. Unexpectedly, in overt-Cushing adenomas, intra-tissular cortisol levels were not higher and androstenedione levels were not lower than in non-functioning adenomas. Adrenal differentiation score based on transcriptome was well correlated with intra-tissular cortisol levels. Conclusion: Discrepancies observed between steroid levels measured in ACT tissue and clinical diagnosis of steroid excess suggest a dysregulation of steroid export depending on tumor type, opening new perspectives for diagnosis and treatment of steroid excess.